Search results
Showing 1606 to 1620 of 8901 results
NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an adequate evidence submission for committee decision-making.
Show all sections
Sections for TA972
Evidence-based recommendations on nivolumab (Opdivo) with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer in adults.
Targeted-release budesonide for treating primary IgA nephropathy (TA1128)
Evidence-based recommendations on targeted-release budesonide (Kinpeygo) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Evidence-based recommendations on tirzepatide (Mounjaro) for managing overweight and obesity in adults.
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency (HST26)
Evidence-based recommendations on eladocagene exuparvovec (Upstaza) for treating aromatic L-amino acid decarboxylase deficiency in people 18 months and over.
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma (TA321)
Evidence-based recommendations on dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma in adults with a BRAF V600 mutation.
Evidence-based recommendations on erythropoiesis-stimulating agents (epoetin alfa [Eprex], epoetin beta [NeoRecormon], epoetin theta, epoeitin zeta [Retacrit] and darbepoetin alfa [Aranesp]) for treating anaemia in adults with cancer having chemotherapy.
Evidence-based recommendations on dual-chamber pacemakers for treating symptomatic bradycardia caused by sick sinus syndrome without atrioventricular block.
Evidence-based recommendations on osimertinib (Tagrisso) for adjuvant treatment of stage 1b to 3a non-small-cell lung cancer after complete tumour resection in adults.
Show all sections
Evidence-based recommendations on glofitamab (Columvi) plus gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma not otherwise specified in adults.
Evidence-based recommendations on ceritinib (Zykadia) for treating advanced anaplastic lymphoma kinase positive non-small-cell lung cancer in adults who have had crizotinib.
Evidence-based recommendations on ruxolitinib (Jakavi). This drug is for adults with disease-related splenomegaly or symptoms caused by primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis, only if they have intermediate-2 or high-risk disease.
Evidence-based recommendations on pixantrone (Pixuvri) for treating relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma in adults.
NICE is unable to recommend the use in the NHS of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti-platelet therapy. This is because The Medicines Company did not provide an evidence submission.
Show all sections
Sections for TA351
NICE is unable to make a recommendation about the use in the NHS of bevacizumab for treating relapsed, platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer. This is because Roche Products did not provide an evidence submission.
Show all sections
Sections for TA353